title: Old world nonhuman primate models of type 2 diabetes mellitus.
abstract: Type 2 diabetes mellitus is a major health problem of increasing incidence. To better study the pathogenesis and potential therapeutic agents for this disease, appropriate animal models are needed. Old World nonhuman primates (NHPs) are a useful animal model of type 2 diabetes; like humans, the disease is most common in older, obese animals. Before developing overt diabetes, NHPs have a period of obesity-associated insulin resistance that is initially met with compensatory insulin secretion. When either a relative or absolute deficiency in pancreatic insulin production occurs, fasting glucose concentrations begin to increase and diabetic signs become apparent. Pathological changes in pancreatic islets are also similar to those seen in human diabetics. Initially there is hyperplasia of the islets with abundant insulin production typically followed by replacement of islets with islet-associated amyloid. Diabetic NHPs have detrimental changes in plasma lipid and lipoprotein concentrations, lipoprotein composition, and glycation, which may contribute to progression of atherosclerosis. As both the prediabetic condition (similar to metabolic syndrome in humans) and overt diabetes become better defined in monkeys, their use in pharmacological studies is increasing. Likely due to their genetic similarity to humans and the similar characteristics of the disease in NHPs, NHPs have been used to study recently developed agonists of the peroxisome proliferators-activated receptors. Importantly, agonists of the different receptor subclasses elicit similar responses in both humans and NHPs. Thus, Old World NHPs are a valuable animal model of type 2 diabetes to study disease progression, associated risk factors, and potential new treatments.
authors.affiliation: Department of Pathology Wake Forest University School of Medicine, Winston-Salem, NC, USA.
authors.forename: Janice E
authors.initials: JE
authors.lastname: Wagner
authors.forename: Kylie
authors.initials: K
authors.lastname: Kavanagh
authors.forename: Gina M
authors.initials: GM
authors.lastname: Ward
authors.forename: Bruce J
authors.initials: BJ
authors.lastname: Auerbach
authors.forename: H James
authors.initials: HJ
authors.lastname: Harwood
authors.forename: Jay R
authors.initials: JR
authors.lastname: Kaplan
mesh_terms: D000818:Animals; D002520:Cercopithecidae; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology / Q000662:veterinary*; D004195:Disease Models, Animal; D005260:Female; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance / Q000502:physiology; D008297:Male; D008992:Monkey Diseases / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D011236:Prediabetic State / Q000378:metabolism / Q000503:physiopathology / Q000662:veterinary*
chemical_list: D007004:Hypoglycemic Agents